CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 503 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $870,317 | -18.7% | 16,114 | +2.6% | 0.01% | -28.6% |
Q1 2024 | $1,070,589 | +50.1% | 15,707 | +37.8% | 0.01% | +16.7% |
Q4 2023 | $713,452 | +179.3% | 11,397 | +102.5% | 0.01% | +100.0% |
Q3 2023 | $255,455 | -25.4% | 5,628 | -7.7% | 0.00% | 0.0% |
Q2 2023 | $342,286 | +26.0% | 6,097 | +1.5% | 0.00% | 0.0% |
Q1 2023 | $271,606 | +6.4% | 6,005 | -4.4% | 0.00% | +50.0% |
Q4 2022 | $255,323 | -99.9% | 6,281 | -53.4% | 0.00% | -60.0% |
Q3 2022 | $440,440,000 | +106030.1% | 13,476 | +97.1% | 0.01% | +25.0% |
Q2 2022 | $415,000 | +22.1% | 6,837 | +26.4% | 0.00% | 0.0% |
Q1 2022 | $340,000 | +4.3% | 5,410 | +25.6% | 0.00% | +33.3% |
Q4 2021 | $326,000 | -76.6% | 4,308 | -65.5% | 0.00% | -78.6% |
Q3 2021 | $1,396,000 | -29.3% | 12,472 | +2.2% | 0.01% | -36.4% |
Q2 2021 | $1,975,000 | +170.9% | 12,200 | +104.0% | 0.02% | +144.4% |
Q1 2021 | $729,000 | -58.0% | 5,981 | -44.3% | 0.01% | -55.0% |
Q4 2020 | $1,735,000 | – | 10,737 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |